What Anthropic's public filing shows about the cost of running AI, plus a robot lab for medicines and photo editors that check their own work.
AppWT Informative Multi-Lingual System
Anthropic, the company that makes the Claude AI assistant, has filed papers to sell shares to the public. The filing shows that running Claude for customers now earns more than it costs, while most of its computer power goes into building new models. If you use AI tools, watch for prices per task and usage limits, since the filing says demand has been bigger than the computer power available.
What Anthropic's filing shows
An IPO, or initial public offering, is when a private company starts selling shares to anyone. Before that, it files a report called an S-1. This report shows its money in detail. Tom's Hardware read the filing and shared these numbers for the first half of this year:
- Anthropic earned $16.3 billion in revenue.
- It spent $2.4 billion serving customers. Serving means running Claude when people use it.
- Its total compute bill was $8.9 billion. Compute means the computer chips and power that run AI.
- Less than a third of that compute went to serving customers. Most of the rest went to training, research and internal use.
Tom's Hardware estimates Anthropic now keeps about 85 cents of each dollar after serving costs, up from 12 cents a year earlier. After partner fees and marketing, that drops to about 66 cents. Research spending grew about five times, and it is the main source of the company's operating loss.
Tom's Hardware also reports that Anthropic's IPO is likely to come before OpenAI's. OpenAI filed confidentially, and its CEO, Sam Altman, said its own IPO won't come this year.
Why it matters to you
People have long asked whether AI companies can cover the cost of running their tools. For Anthropic, serving Claude now more than pays for itself, according to the Tom's Hardware analysis.
Prices per task have also been falling. In September, the company said its Opus 5.5 model cut costs per task by about 40% compared with Opus 5. Its Fable 5.1 model cut typical costs by about 25% compared with Fable 5. The company says this came from "a combination of a lower price and improved efficiency."
The bigger question is the future bill. By Tom's Hardware's math, Anthropic has signed up for roughly $800 billion more in chip capacity. Its five largest deals could cost an estimated $103 billion a year on average once delivered. That is more than twice its current revenue pace of about $46 billion a year. The company itself warns that its margins, the share it keeps from each sale, may shrink as new hardware arrives before the revenue it will support.
Anthropic uses chips from several makers: AWS Trainium, Google TPUs, Nvidia GPUs and AMD GPUs.
A robot lab for medicine research
The Robot Report says a startup called Warp Sciences came out of stealth, meaning it stopped working in secret. It has $215 million in funding and is based in South San Francisco.
Warp is building a U.S.-based chemistry contract research organization, or CRO. A CRO is a company that does lab work for other research teams. Warp plans to combine chemists, robots and AI to make and test molecules. Its first service will make small variations of molecules, so scientists can compare them while searching for a drug candidate.
Warp does not plan to make its own drugs. It wants its labs to produce real experiment data that can train better AI. Its CEO, Kevin Weil, most recently worked at OpenAI. He said, "Chemistry and biology move forward when you make something, test it and learn from the result."
Warp also points to the BIOSECURE Act, a U.S. law signed in December 2025. It sets up limits on federal buying and funding involving certain biotech companies. Warp says it wants to give customers more control over where sensitive research takes place.
Photo editing AI that checks its work
A research paper on Hugging Face Papers describes EditAgent. It is a system for "agentic" image editing. That means an AI breaks a big photo edit request into smaller steps and does them one at a time.
The authors say a general editing tool gave no usable result in over 40% of cases on their test set. EditAgent sends each step to a fitting tool, including special tools for certain jobs. It also attaches a record of how each result was checked. It makes several versions at once and judges them together. Experts preferred this method in 78.5% of comparisons where they picked a winner, with half the checks or fewer.
This is still research, and the results come from the authors themselves.
What to watch next
- Whether Anthropic's public offering goes ahead, and when.
- Whether AI prices per task keep falling as new chips come online.
- Whether robot labs like Warp's speed up early drug research.
- Whether self-checking photo editors reach everyday apps.
Have a question about anything here? Email me at sales@appwt.com or call (888) 565-0171, and I will answer it.
Sources
- Anthropic's IPO filing shows most of its compute goes to R&D, not serving customers, Tom's Hardware, 2026-10-29
- Warp Sciences emerges from stealth, to apply robotics to drug research, The Robot Report, 2026-10-28
- EditAgent: Rethinking Agentic Image Editing, Hugging Face Papers, 2026-10-28
Tags
Frequently Asked Questions
What is an S-1 filing?
It is a report a company files before it sells shares to the public. It shows the company's money in detail. Anthropic's S-1 shows its revenue, costs and computer spending.
Does Anthropic make money running Claude?
According to Tom's Hardware, yes. It spent $2.4 billion serving customers in the first half of the year and earned $16.3 billion in revenue. The company still has an operating loss, mainly from research spending.
Where does most of Anthropic's computer power go?
Less than a third of its $8.9 billion first-half compute bill went to serving customers. Most of the rest went to training, research and running Claude internally.
What does Warp Sciences do?
It is building a U.S.-based lab that uses chemists, robots and AI to make and test molecules for drug research teams. It does not plan to make its own drugs.
Is EditAgent available in photo apps today?
The source describes it as a research paper. The results reported come from its authors.
Enjoyed this article?
Share it with your network
